Open AccessEvidence‐Based Oral Transmucosal Fentanyl Citrate (OTFC ® ) Dosing Guidelines
Author(s) -
Aronoff Gerald M.,
Brennan Michael J.,
Pritchard Douglas D.,
Ginsberg Brian
Publication year - 2005
Publication title -
pain medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 97
eISSN - 1526-4637
pISSN - 1526-2375
DOI - 10.1111/j.1526-4637.2005.00045.x
Subject(s) - dosing , medicine , fentanyl , cancer pain , opioid , anesthesia , intensive care medicine , breakthrough pain , pharmacology , cancer , receptor
ABSTRACT Objective. To review the evidence for dosing and efficacy of oral transmucosal fentanyl citrate in the management of pain and produce dosing guidelines. Design. The scientific literature pertaining to oral transmucosal fentanyl citrate was reviewed, focusing upon its pharmacology and clinical experience with use in cancer and noncancer pain. Emphasis was upon published, peer‐reviewed English language articles. Results. Information was crucially examined and synthesized into guidelines for use and dosing of oral transmucosal fentanyl citrate in cancer and noncancer pain. Conclusions. Oral transmucosal fentanyl citrate is a potent opioid delivery system, which, when used appropriately, is an effective treatment option for pain. Adherence to guidelines should promote its safe and efficacious use in a variety of clinical pain management settings.